2seventy bio, Inc. (TSVT) Stock Price, News, Quote & History
Find the latest 2seventy bio, Inc. (TSVT) stock quote, history, news and other vital information to help you with your stock trading and investing.
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
2seventy bio Announces Completion of Oncology and …
CAMBRIDGE, Mass., April 01, 2024--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement ("APA") by Regeneron Pharmaceuticals, Inc.
2seventy bio, Inc. (TSVT) Latest Press Releases & Corporate News ...
Get the latest 2seventy bio, Inc. (TSVT) stock news and headlines to help you in your trading and investing decisions.
2seventy bio Announces New Strategic Path Forward - Yahoo …
CAMBRIDGE, Mass., January 30, 2024--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma ...
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
Feb 6, 2024 · Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
All You Need to Know About 2seventy bio, Inc. (TSVT) Rating …
Jan 12, 2024 · 2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2seventy bio Inc (TSVT) Reports Mixed Financial Results Amid …
Mar 5, 2024 · 2seventy bio Inc (NASDAQ:TSVT) reported a net loss that was smaller compared to the previous year, indicating some improvement in financial health. The company's strategic realignment and the ...
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial ...
Mar 5, 2024 · (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2023.
Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback
Nov 21, 2023 · BMY and TSVT are jointly developing and commercializing Abecma in the United States. Both companies anticipate that the committee will review data related to the secondary endpoint of overall ...